Palatin Technologies (PTN) Q2 2026 earnings summary

Executive summary

• Advanced melanocortin receptor (MC4R and MC1R) agonist pipeline targeting rare neuroendocrine and genetic obesity disorders, with lead programs in hypothalamic obesity and Prader-Willi syndrome, and additional indications in ocular, gastroenterology, and renal diseases.

• Strengthened financial position through an $18.2 million public offering, regained NYSE American listing compliance, and improved operational flexibility.

• Entered a major research collaboration and license agreement with Boehringer Ingelheim for retinal disease therapeutics, generating significant upfront and milestone revenue.

• Sublicensed PL9643 for dry eye disease, receiving $3.8 million in upfront non-cash debt cancellation and eligibility for future milestones and royalties.

Financial highlights

• Collaboration and license revenue for the six months ended December 31, 2025, was $8.96 million, with $116,036 recognized in Q2 FY26, mainly from the Boehringer Ingelheim agreement.

• Operating expenses rose to $7.4 million for the quarter, up from $2.6 million year-over-year, driven by increased R&D and higher compensation and professional fees.

• Net loss for Q2 FY26 was $7.3 million ($2.86/share), compared to $2.4 million ($5.92/share) in the prior year.

• Cash and cash equivalents were $14.5 million as of December 31, 2025, up from $1.3 million at September 30, 2025.

• Net cash used in operations was $4.8 million, consistent with the prior year.

Outlook and guidance

• Cash runway expected to extend beyond March 31, 2027, supporting advancement of both oral and injectable obesity programs.

• IND submission for lead oral MC4R agonist (PL7737) planned for 1H 2026, with phase 1 SAD/MAD trial initiation on track; next-generation peptide agonist IND submission targeted for 2H 2026.

• Multiple clinical trials for rare MC4R pathway diseases are planned for calendar year 2026.

• Phase II/III studies in hypothalamic obesity and Prader-Willi syndrome not expected to start before mid-2027.

• Additional funding will be required to complete clinical trials and regulatory submissions for product candidates.